Corcept Therapeutics Inc (CORT) 1.84 $CORT
Corcept Plunges on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:35PM CDT
Shares of Corcept Therapeutics Inc. (CORT) were down 50.5% after the company announced that it will discontinue the study on Korlym (study 14) for the treatment of psychotic depression.
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Why Corcept Therapeutics Incorporated Shares Were Mauled
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 12:44PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Corcept Therapeutics , a biopharmaceutical...
Why Corcept Therapeutics (CORT) Is Plummeting Today
at The Street - Wed May 07, 11:05AM CDT
Corcept Therapeutics (CORT) plummeted Wednesday after the company stopped a late-stage trial of its depression treatment drug Mifepristone after analysis determined it was unlikely to succeed.
Stock to Watch: Corcept Therapeutics Down 50.0% (CORT)
Comtex SmarTrend(R) - Wed May 07, 10:10AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 50.0% to $2.01 on 3.7x average daily volume. Corcept Therapeutics has traded 2.3 million shares thus far today, vs. average volume of 620,000 shares per day. The stock has underperformed the Dow (-50.0% to the Dow's 0.1%) and underperformed the S&P 500 (-50.0% to the S&P's -0.0%) during today's trading.
Corcept Therapeutics Announces First Quarter 2014 Financial Results
Marketwire - Wed May 07, 7:32AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the quarter ended March 31, 2014. The company also reported that it is discontinuing its Phase 3 psychotic depression study (Study 14) based on the recommendation of the study's data monitoring committee that the study was unlikely to meet its primary endpoint with statistical significance.
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
Marketwire - Wed Apr 30, 3:32PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 7, 2014. The Company will also host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:39AM CDT
Corcept Therapeutics could beat earnings estimates this season backed by favorable earnings estimate revision activity
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
Corcept Therapeutics (CORT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:39AM CDT
Corcept Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Hot Stock: Corcept Therapeutics, Shares Gain 13.5% (CORT)
Comtex SmarTrend(R) - Fri Mar 28, 11:41AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 13.5% to $4.38 on 1.2x average daily volume. Corcept Therapeutics has traded 641,000 shares thus far today, vs. average volume of 540,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
Will Corcept Therapeutics (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:45AM CDT
Will Corcept Therapeutics (CORT) Continue to Surge Higher?
Corcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 8:02AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2013.
Corcept Therapeutics Up 9.5%, Shares Break Through Resistance (CORT)
Comtex SmarTrend(R) - Tue Mar 04, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 9.5% to $3.69 on 1.0x average daily volume. Corcept Therapeutics has traded 464,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has outperformed the Dow (9.5% to the Dow's 1.2%) and outperformed the S&P 500 (9.5% to the S&P's 1.3%) during today's trading.
TransCanada Files 2013 Annual Disclosure Documents
Marketwire Canada - Fri Feb 21, 3:26PM CST
TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) has today filed with Canadian securities authorities:
Traders Get Bullish on Shares of Corcept Therapeutics, Shares Up 6.9% (CORT)
Comtex SmarTrend(R) - Wed Feb 12, 11:41AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 6.9% to $3.25 on 2.8x average daily volume. Corcept Therapeutics has traded 1.3 million shares thus far today, vs. average volume of 473,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.2%) and outperformed the S&P 500 (6.9% to the S&P's 0.0%) during today's trading.
Revenue Update from Corcept - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 3:50PM CST
Corcept expects to generate revenues of $4.1 million in the fourth quarter of 2013, above the Zacks Consensus Estimate of $3.0 million.
Why Corcept Therapeutics Incorporated Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 31, 2:26PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Corcept Therapeutics , a biopharmaceutical...
Corcept Therapeutics Down 8.0%, Shares Slide into the Red (CORT)
Comtex SmarTrend(R) - Fri Jan 31, 10:11AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.0% to $3.43 on 1.2x average daily volume. Thus far today, Corcept Therapeutics has traded 578,000 shares, vs. average volume of 497,000 shares per day. The stock has underperformed the Dow (-8.0% to the Dow's -1.1%) and underperformed the S&P 500 (-8.0% to the S&P's -0.8%) during today's trading.
Corcept Therapeutics Announces Fourth Quarter, Full Year 2013 Revenue and Provides 2014 Outlook
Marketwire - Thu Jan 30, 3:06PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT)
Corcept Plunges on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:35PM CDT
Shares of Corcept Therapeutics Inc. (CORT) were down 50.5% after the company announced that it will discontinue the study on Korlym (study 14) for the treatment of psychotic depression.
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Why Corcept Therapeutics Incorporated Shares Were Mauled
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 12:44PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Corcept Therapeutics , a biopharmaceutical...
Why Corcept Therapeutics (CORT) Is Plummeting Today
at The Street - Wed May 07, 11:05AM CDT
Corcept Therapeutics (CORT) plummeted Wednesday after the company stopped a late-stage trial of its depression treatment drug Mifepristone after analysis determined it was unlikely to succeed.
Stock to Watch: Corcept Therapeutics Down 50.0% (CORT)
Comtex SmarTrend(R) - Wed May 07, 10:10AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 50.0% to $2.01 on 3.7x average daily volume. Corcept Therapeutics has traded 2.3 million shares thus far today, vs. average volume of 620,000 shares per day. The stock has underperformed the Dow (-50.0% to the Dow's 0.1%) and underperformed the S&P 500 (-50.0% to the S&P's -0.0%) during today's trading.
Corcept Therapeutics Announces First Quarter 2014 Financial Results
Marketwire - Wed May 07, 7:32AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the quarter ended March 31, 2014. The company also reported that it is discontinuing its Phase 3 psychotic depression study (Study 14) based on the recommendation of the study's data monitoring committee that the study was unlikely to meet its primary endpoint with statistical significance.
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
Marketwire - Wed Apr 30, 3:32PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 7, 2014. The Company will also host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:39AM CDT
Corcept Therapeutics could beat earnings estimates this season backed by favorable earnings estimate revision activity
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. Corcept Therapeutics (CORT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:39AM CDT
Corcept Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Hot Stock: Corcept Therapeutics, Shares Gain 13.5% (CORT)
Comtex SmarTrend(R) - Fri Mar 28, 11:41AM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 13.5% to $4.38 on 1.2x average daily volume. Corcept Therapeutics has traded 641,000 shares thus far today, vs. average volume of 540,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's 0.7%) and outperformed the S&P 500 (13.5% to the S&P's 0.7%) during today's trading.
Will Corcept Therapeutics (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:45AM CDT
Will Corcept Therapeutics (CORT) Continue to Surge Higher?
Corcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 8:02AM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2013.
Corcept Therapeutics Up 9.5%, Shares Break Through Resistance (CORT)
Comtex SmarTrend(R) - Tue Mar 04, 10:14AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 9.5% to $3.69 on 1.0x average daily volume. Corcept Therapeutics has traded 464,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has outperformed the Dow (9.5% to the Dow's 1.2%) and outperformed the S&P 500 (9.5% to the S&P's 1.3%) during today's trading.
TransCanada Files 2013 Annual Disclosure Documents
Marketwire Canada - Fri Feb 21, 3:26PM CST
TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) has today filed with Canadian securities authorities:
Traders Get Bullish on Shares of Corcept Therapeutics, Shares Up 6.9% (CORT)
Comtex SmarTrend(R) - Wed Feb 12, 11:41AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's best performing low-priced stocks, up 6.9% to $3.25 on 2.8x average daily volume. Corcept Therapeutics has traded 1.3 million shares thus far today, vs. average volume of 473,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's -0.2%) and outperformed the S&P 500 (6.9% to the S&P's 0.0%) during today's trading.
Revenue Update from Corcept - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 3:50PM CST
Corcept expects to generate revenues of $4.1 million in the fourth quarter of 2013, above the Zacks Consensus Estimate of $3.0 million.
Why Corcept Therapeutics Incorporated Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 31, 2:26PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Corcept Therapeutics , a biopharmaceutical...
Corcept Therapeutics Down 8.0%, Shares Slide into the Red (CORT)
Comtex SmarTrend(R) - Fri Jan 31, 10:11AM CST
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.0% to $3.43 on 1.2x average daily volume. Thus far today, Corcept Therapeutics has traded 578,000 shares, vs. average volume of 497,000 shares per day. The stock has underperformed the Dow (-8.0% to the Dow's -1.1%) and underperformed the S&P 500 (-8.0% to the S&P's -0.8%) during today's trading.
Corcept Therapeutics Announces Fourth Quarter, Full Year 2013 Revenue and Provides 2014 Outlook
Marketwire - Thu Jan 30, 3:06PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT)
